This 75-minute webinar is centred around data from trials investigating the efficacy and safety of aducanumab, an investigational treatment for early Alzheimer’s disease. Featured in the webinar is ADI’s Chief Executive Paola Barbarino; Dr. Alireza Atri, Chair of ADI’s Medical and Scientific Advisory Panel and Biogen’s Head of Neurodegeneration, Dr. Samantha Budd Haeberlein.
In the webinar, Dr. Haeberlein presents the data from Biogen’s Phase 3 clinical studies ENGAGE and EMERGE. Dr Haeberlein also goes into detail as to why Biogen’s Phase 3 clinical trials for the investigative Alzheimer’s drug was prematurely terminated in 2019 and how the full data set provides evidence of clinical effectiveness.
As of January 2021, aducanumab is currently under regulatory review in the United States, the European Union and Japan. If approved, the investigational drug would be the first disease-modifying treatment for Alzheimer’s disease.
Following a question and answer session at the end of Dr. Haeberlein’s presentation, Dr. Atri emphasised:
From these two studies, the results were positive… several efficacy measures were used and they were all convergent. There is no disagreement that there was a clear effect on the target and this showed positive clinical outcomes. But we have to be honest: this is not a cure, this is something that is modest – to manage someone’s Alzheimer’s. It would be a first generation drug that we can learn from.